Inflammatory Mediators of Acute Kidney Injury in Intensive Care

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUppsala University

About this trial

Acute kidney injury (AKI) affects more than 50% of patients admitted to the intensive care unit. The most common underlying cause is sepsis. Severe AKI in combination with sepsis is associated with high mortality. The mechanisms for sepsis-induced AKI are largely unknown. Our hypothesis is that the inflammatory response to an infection cause collateral damage to host tissue and contributes to the development of AKI. In this study we want to investigate the presence of novel inflammatory mediators in patients with sepsis, patients subjected to major surgery (sterile inflammation) and non-inflamed patients and correlate their levels with the risk for AKI.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

with septic shock or

post major surgery or

after intoxication with a chemical compund

Disqualifiers

Pregnancy or

Breast feeding or

Chronic kidney disease or

intoxication with nephrotoxic compund or

Trial population

Patients subjected to major surgery or intensive care

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

100 Participants
are grouped into 3 trial groups
Group A: Sepsis
Group B: Surgery
Group C: Non-inflamed

Trial outcomes

Primary outcomes

1

Histones

Correlation between levels of histones and degree of acute kidney injury

Time frame
Within 1 month

Secondary outcomes

1

Other inflammtory mediators

Correlation between levels of other inflammtory mediators and degree of acute kidney injury

Time frame
Within 1 month

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Uppsala University

Lead sponsor

Maastricht University

Collaborator